Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 2,901–3,000 of 15,747
Boosting CAR-T cell therapy through vaccine synergy
Li, Y.-R., Lyu, Z., Shen, X., Fang, Y., & Yang, L. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.12.004 · Cited by 46
COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis
Briggs, F. B. S., Mateen, F. J., Schmidt, H. K., Currie, K. M., Siefers, H. M., Crouthamel, S., Bebo, B. F., Fiol, J., Racke, M. K., O'Connor, K. C., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001104 · Cited by 42
“S, andChAdOx1 nCoV-19 from vaccine trials and observational studies of the general population has been characterized by transient and mild to moderate symptoms, including pain at the injection site, headache, fatigue, fever/ chills, and myalgia.(2,5,9,10) On average, a higher proportion of women, younger adults, and t…”
BackgroundBuilding CRISPR Gene Therapies for the Central Nervous System: A Review
Salomonsson, S. E., & Clelland, C. D. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2023.4983 · Cited by 46
The basis of a more contagious 501Y.V1 variant of SARS-COV-2
Liu, H.-L., Zhang, Q.-Q., Wei, P., et al. (2021) · bioRxiv · doi:10.1101/2021.02.02.428884 · Cited by 2
ACE2‐based decoy receptors for SARS coronavirus 2
Jing, W., & Procko, E. (2021) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26140 · Cited by 35
Kavanagh, E. W., Tzeng, S. Y., Sharma, N., Cutting, G. R., & Green, J. J. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122753 · Cited by 41
Tani, N., Chong, Y., Kurata, Y., Gondo, K., Oishi, R., Goto, T., Minami, J., Onozawa, K., Nagano, S., Shimono, N., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.025 · Cited by 39
“Of these, BNT162b2mRNA coronavirus disease 2019 (COVID-19) vaccine (Pfizer, Inc., and BioNTech) has been reported to be 95% effective in preventing symptomatic COVID- 19 [1].”
InfluentialLiu, L., Kim, J.-H., Li, Z., Sun, M., Trent, N., Tang, Y. J., Mcintosh, E., Karve, S., & DeRosa, F. (2025) · Nanoscale · doi:10.1039/d5nr00433k · Cited by 50
Hu, S., Xiong, C., Li, Q., Wang, Z., & Jiang, Y. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.07.051 · Cited by 35
“Phase III clinical trials have provided strong evidence of vaccine efficacy [3,36,40].”
BackgroundA COVID-19 vaccination model for Aotearoa New Zealand
Steyn, N., Plank, M. J., Binny, R. N., Hendy, S. C., Lustig, A. G., & Ridings, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-06707-5 · Cited by 35
RETRACTED: Why are we vaccinating children against COVID-19?
Kostoff, R. N., Călina, D. C., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P. G., Svistunov, A. А., & Tsatsakis, A. M. (2021) · Toxicology Reports · doi:10.1016/j.toxrep.2021.08.010 · Cited by 50
RetractedNatural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis
Craven, B., Lester, W., Boyce, S., Thomas, W., Kanny, A., Davies, C. R., Pavord, S. R., Hermans, J., Makris, M., Bart‐Smith, E., et al. (2022) · Blood · doi:10.1182/blood.2021014684 · Cited by 39
Svitkin, Y. V., Gingras, A., & Sonenberg, N. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1241 · Cited by 43
“Furthermore, these vaccines have proven to be nearly 95% effective in preventing COVID-19 (5,6).”
Epigenetic adjuvants: durable reprogramming of the innate immune system with adjuvants
Lee, A. W. Q., Wimmers, F., & Pulendran, B. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102189 · Cited by 45
Novak, F., Nilsson, A. C., Nielsen, C., Holm, D. K., Østergaard, K., Bystrup, A., Byg, K., Johansen, I. S., Mittl, K., Rowles, W. M., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103251 · Cited by 41
Lee, S., Sankhala, K. K., Bose, S., & Gallemore, R. P. (2022) · International Medical Case Reports Journal · doi:10.2147/imcrj.s328931 · Cited by 37
“Numerous clinical trials demonstrated safety and efficacy with a low complication rate.(3,4) Select patients, however, have experienced complications, and vascular thrombosis has been one of them.”
BackgroundSevere allergic reactions to the COVID-19 vaccine – statement and practical consequences
Kleine‐Tebbe, J., Klimek, L., Hamelmann, E. H., et al. (2021) · Allergologie select · doi:10.5414/alx02215e · Cited by 37
McEllistrem, M. C., Clancy, C. J., Buehrle, D. J., LUCAS, A. E., & Decker, B. K. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab263 · Cited by 41
Tetrahydropyrimidine Ionizable Lipids for Efficient mRNA Delivery
Isaac, I., Shaikh, A., Bhatia, M., Liu, Q., Park, S., & Bhattacharya, C. (2024) · ACS Nano · doi:10.1021/acsnano.4c10154 · Cited by 40
SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies
Mlčochová, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Mishra, S., Whittaker, C., Mellan, T. A., Ferreira, I. A. T. M., Datir, R. P., et al. (2021) · Greater South Information System · doi:10.60692/dy28a-h7650 · Cited by 61
Upadhyay, A. A., Viox, E. G., Hoang, T. N., Boddapati, A. K., Pino, M., Lee, M. Y.-H., Corry, J., Strongin, Z., Cowan, D. A., Beagle, E. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37425-9 · Cited by 40
COVID-19 deaths and hospitalizations averted by rapid vaccination rollout in the United StatesPreprint
Moghadas, S. M., Sah, P., Fitzpatrick, M. C., Shoukat, A., Pandey, A., VILCHES, T. N., Singer, B. H., Schneider, E. C., & Galvani, A. P. (2021) · medRxiv · doi:10.1101/2021.07.07.21260156 · Cited by 36
Li, Z., Liu, S., Li, F., Li, Y., Li, Y., Peng, P., Li, S., Li, H., & Liu, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965971 · Cited by 44
Kawano, Y., Patel, N. J., Wang, X., Cook, C., Vanni, K. M. M., Kowalski, E., Banasiak, E., Qian, G., DiIorio, M. A., Hsu, T. Y. T., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222954 · Cited by 38
Shroff, R., Chalasani, P., Wei, R., et al. (2021) · medRxiv · doi:10.1101/2021.05.13.21257129 · Cited by 33
“With high rates of transmission, even mitigation strategies have not been enough to decrease mortality rates from COVID-19 in patients with active cancer.”
InfluentialRational design of lipid nanoparticles for enabling gene therapies
Brimacombe, C. A., Kulkarni, J. A., Cheng, M. H. Y., An, K., Witzigmann, D., & Cullis, P. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101518 · Cited by 56
“6,7,196 The success of LNP mRNA systems as COVID-19 vaccines has led to extensive efforts to develop mRNA vaccines against a variety of infectious diseases and cancer as summarized elsewhere.”
COVID-19 vaccines: Immune correlates and clinical outcomes
Mahrokhian, S. H., Tostanoski, L. H., Vidal, S. J., & Barouch, D. H. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2324549 · Cited by 46
Immune thrombocytopenic purpura after SARS‐CoV‐2 vaccine
Candelli, M., Rossi, E., Valletta, F., Stefano, V. D., & Franceschi, F. (2021) · British Journal of Haematology · doi:10.1111/bjh.17508 · Cited by 45
Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine
Azzi, L., Gasperina, D. D., Veronesi, G., Shallak, M., Maurino, V., Baj, A., Gianfagna, F., Cavallo, P., Dentali, F., Tettamanti, L., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2022.104435 · Cited by 41
COVID-19 and vaccination: myths vs science
Chavda, V. P., Chen, Y., Dave, J. B., Chen, Z., Chauhan, S. C., Yallapu, M. M., Uversky, V. N., Bezbaruah, R., Patel, S., & Apostolopoulos, V. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2114900 · Cited by 39
Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases
Bakasis, A., Bitzogli, K., Mouziouras, D., Pouliakis, A., Roumpoutsou, M., Goules, A. V., & Ανδρουτσάκος, Θ. (2022) · Viruses · doi:10.3390/v14020207 · Cited by 39
Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients
Phadke, V. K., Scanlon, N., Jordan, S. C., & Rouphael, N. (2021) · Current Transplantation Reports · doi:10.1007/s40472-021-00322-5 · Cited by 39
Srinivash, M., Krishnamoorthi, R., Mahalingam, P. U., Malaikozhundan, B., Bharathakumar, S., Gurushankar, K., Dhanapal, K., Samy, K. K., & Perumal, A. B. (2023) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2023.110682 · Cited by 38
“(BNT162b2) NCT04368728 USA 95 mRNA Tolerability and immunogenicity from different strain [231]”
BackgroundLow baseline IFN-γ response could predict hospitalization in COVID-19 patients
Crémoni, M., Allouche, J., Graça, D., Zorzi, K., Fernandez, C., Teisseyre, M., Benzaken, S., Ruetsch-Chelli, C., Esnault, V. L. M., Dellamonica, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953502 · Cited by 46
SFTSV Gn‐Head mRNA vaccine confers efficient protection against lethal viral challenge
Kim, D.-K., Lai, C., Cha, I., Kang, S., Yang, W., Choi, Y., & Jung, J. U. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29203 · Cited by 39
“38,39 The mRNA vaccines have also proven to be effective in eliciting immunity among the vaccinated populations, as shown by a substantial reduction in severe cases of COVID ‐ 19 leading to hospitalization or fatal infections.”
BackgroundHamm, S. R., Rezahosseini, O., Møller, D. L., Loft, J. A., Poulsen, J. R., Knudsen, J. D., Pedersen, M. S., Schønning, K., Harboe, Z. B., Rasmussen, A., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17141 · Cited by 39
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management
Luxi, N., Giovanazzi, A., Arcolacı, A., Bonadonna, P., Crivellaro, M., Cutroneo, P. M., Ferrajolo, C., Furci, F., Guidolin, L., Moretti, U., et al. (2022) · BioDrugs · doi:10.1007/s40259-022-00536-8 · Cited by 39
Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness
Tulimilli, S. V., Dallavalasa, S., Basavaraju, C. G., Rao, V. K., Chikkahonnaiah, P., Madhunapantula, S. V., & Veeranna, R. P. (2022) · Vaccines · doi:10.3390/vaccines10101751 · Cited by 43
“1 BNT162b2 (Comirnaty) mRNA-based vaccine Pfizer, BioNTech; Fosun Pharma SARS-CoV-2: 95% [76] Omicron: 70% [22] Safety over a median of 2 months was similar to that of other viral vaccines Two doses”
BackgroundResultInfluentialYang, J., Ko, J., Baek, J. Y., Hong, J., Ha, S., Lee, B., Huh, K., Cho, S. Y., Kang, C., Chung, D. R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744206 · Cited by 39
“eDiary for Reactogenicity The reactogenicity data after the first dose of vaccination were collected for seven days using an electronic diary (eDiary) format, whichwas developedbasedonphase III clinical trials of the vaccines (1, 2).”
BackgroundMethodTerpos, E., Zagouri, F., Liontos, M., Sklirou, A. D., Koutsoukos, K., Markellos, C., Briasoulis, Α., Papanagnou, E., Trougakos, I. P., & Dimopoulos, M. A. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01099-x · Cited by 36
“However, patients with cancer were excluded from SARSCoV-2 vaccines registrational trials [2, 3] and we lack data regarding the safety and efficacy of vaccination in this population.”
BackgroundDziedzic, A. M., Riad, A., Attia, S., Klugar, M., & Tanasiewicz, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10225338 · Cited by 44
“Official clinical trials showed that these two most predominantly used COVID-19 vaccines have acceptable safety profiles [57,58].”
COVID-19 vaccine acceptance and rejection in an adult population in Bosnia and Herzegovina
Fojnica, A., Osmanović, A., Đuzić, N., Fejzic, A., Mekić, E., Gromilić, Z., Muhović, I., & Kurtović-Kozarić, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264754 · Cited by 48
SARS-CoV-2 transmission across age groups in France and implications for control
Kiem, C. T., Bosetti, P., Paireau, J., Crépey, P., Salje, H., Lefrancq, N., Fontanet, A. L., Benamouzig, D., Boëlle, P., Desenclos, J. C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27163-1 · Cited by 43
Almendro-Vázquez, P., Chivite‐Lacaba, M., Utrero‐Rico, A., González‐Cuadrado, C., Laguna‐Goya, R., Moreno-Batanero, M., Sánchez-Paz, L., Luczkowiak, J., Labiod, N., Folgueira, M. D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.981350 · Cited by 40
“Vaccination side effects were more frequent among subjects with prior SARS-CoV-2 infection compared to naïve subjects (Figure S1), and increased their frequency with subsequent vaccine doses (median [IQR] number of side effects after the first, second and third doses were 2 [2-3], 4 [2-6] and 5 [3-7], respectively).”
BackgroundAcute myocarditis following administration of BNT162b2 vaccine
Habib, M. B., Hamamyh, T., Elyas, A. A., Altermanini, M., & Elhassan, M. (2021) · IDCases · doi:10.1016/j.idcr.2021.e01197 · Cited by 38
“However, the long-term side effects are still under investigation [3].”
BackgroundYechezkel, M., Mofaz, M., Painsky, A., Patalon, T., Gazit, S., Shmueli, E., & Yamin, D. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00407-6 · Cited by 38
Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines
Gaspar, E. B., Prudêncio, C. R., & Gaspari, E. D. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1920272 · Cited by 37
Geanes, E. S., LeMaster, C., Fraley, E., Khanal, S., McLennan, R., Grundberg, E., Selvarangan, R., & Bradley, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-10230-y · Cited by 38
Efficacy and safety of COVID‐19 vaccines: A network meta‐analysis
Toubasi, A. A., Al-Sayegh, T., Obaid, Y. Y., Al‐Harasis, S. M., & AlRyalat, S. A. (2022) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12492 · Cited by 37
“placebo 3 (48,992) 115/15,361 338/15,217 0.”
Porello, I., Bono, N., Candiani, G., & Cellesi, F. (2024) · Polymer Chemistry · doi:10.1039/d4py00234b · Cited by 42
Ionizable polymeric micelles (IPMs) for efficient siRNA delivery
Zhou, Z., Yu, F., Jiang, M., Yao, Z., Wang, J., Pan, F., Feng, R., Zhao, C., Ma, Y., Zhou, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55721-w · Cited by 49
Schmidt, P., Narayan, K. M., Li, Y., Kaku, C. I., Brown, M. E., Champney, E. R., Geoghegan, J. C., Vásquez, M., Krauland, E. M., Yockachonis, T. J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg2783 · Cited by 36
“In contrast, certain mRNA vaccines have demonstrated peak efficacies of about 95%, despite inducing similar or lower levels of serum neutralization as those achieved in monoclonal antibody efficacy studies (27, 30).”
BackgroundMethodThe COVID-19 vaccine development: A pandemic paradigm
Carneiro, D. D. C., Sousa, J. D. O., & Monteiro-Cunha, J. P. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198454 · Cited by 44
Vaccine efficacy probable against COVID-19 variants
Luchsinger, L. L., & Hillyer, C. D. (2021) · Science · doi:10.1126/science.abg9461 · Cited by 34
Zhang, H., Bussmann, J., Huhnke, F. H., Devoldere, J., Minnaert, A., Jiskoot, W., Serwane, F., Spatz, J. P., Röding, M., Smedt, S. C. D., et al. (2021) · Advanced Science · doi:10.1002/advs.202102072 · Cited by 38
Zhang, W., Hou, Y., Yin, S., Miao, Q., Lee, K., Zhou, X., & Wang, Y. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02580-8 · Cited by 47
Highly efficient mRNA delivery with nonlinear microfluidic cell stretching for cellular engineering
Kwon, C., & Chung, A. J. (2023) · Lab on a Chip · doi:10.1039/d2lc01115h · Cited by 37
mRNA-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-CoV-2 Omicron VariantPreprint
Garcia-Beltran, W. F., Denis, K. S., Hoelzemer, A., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3985605 · Cited by 37
Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era
Coyle, P. K., Gocke, A. R., Vignos, M., & Newsome, S. D. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01761-3 · Cited by 45
“BNT162b2 and mRNA-1273 contain lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the SARSCoV-2 full-length spike protein but modified by two proline mutations [53, 168], and are administered in two doses [169].”
BackgroundInfluentialSerafim, M. S. M., dos Santos, V. S., Gertrudes, J. C., Maltarollo, V. G., & Honório, K. M. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1918098 · Cited by 39
“…by COVID-19, a few months were enough to show that a global effort led to the development, availability, production and distribution of several vaccine candidates against SARS-CoV-2 [28,29], including an approved RNA (ribonucleic acid) vaccine developed by Pfizer-BioNTech in less than a year [31].”
BackgroundCOVID-19 Vaccines, Effectiveness, and Immune Responses
Abufares, H. I., Alsoud, L. O., Alqudah, M. A. Y., Shara, M., Soares, N. C., Alzoubi, K. H., El‐Huneidi, W., Bustanji, Y. K., Soliman, S. S. M., & Semreen, M. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315415 · Cited by 51
Settanni, G., Brill, W., Haas, H., & Schmid, F. (2021) · Macromolecular Rapid Communications · doi:10.1002/marc.202100683 · Cited by 42
Pollett, S. D., Richard, S. A., Fries, A. C., Simons, M. P., Mende, K., Lalani, T., Lee, T., Chi, S., Mody, R. M., Madar, C., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab543 · Cited by 47
John, B. V., Deng, Y., Khakoo, N. S., Taddei, T. H., Kaplan, D. E., & Dahman, B. A. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.11.001 · Cited by 40
COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis
Faissner, S., Richter, D., Ceylan, U., Schneider‐Gold, C., & Gold, R. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10768-3 · Cited by 37
Impact of Obesity on Vaccination to SARS-CoV-2
Nasr, M.-J. C., Geerling, E., & Pinto, A. K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.898810 · Cited by 43
“In this phase III trial, 13,218 subjects were classified as having obesity based on a BMI ≥ 30 kg/m(2) (53).”
BackgroundMethodInfluentialPerformance of Antigen Detection Tests for SARS-CoV-2: A Systematic Review and Meta-Analysis
Tapari, A., Braliou, G. G., Papaefthimiou, M., Mavriki, H., Kontou, P. I., Nikolopoulos, G. K., & Bagos, P. G. (2022) · Diagnostics · doi:10.3390/diagnostics12061388 · Cited by 38
Splenic B cell-targeting lipid nanoparticles for safe and effective mRNA vaccine delivery
Suzuki, Y., Yakuwa, M., Sato, M., Samaridou, E., Beck-Broichsitter, M., Maeki, M., Tokeshi, M., Yamada, Y., Harashima, H., & Sato, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113687 · Cited by 37
COVID-19 vaccine induced interstitial lung disease
Yoshifuji, A., Ishioka, K., Masuzawa, Y., Suda, S., Murata, S., Uwamino, Y., Fujino, M., Miyahara, H., Hasegawa, N., Ryuzaki, M., et al. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.09.010 · Cited by 36
“However, no vaccination-associated deaths have been observed [4].”
BackgroundAgrati, C., Castilletti, C., Goletti, D., Sacchi, A., Bordoni, V., Mariotti, D., Notari, S., Matusali, G., Meschi, S., Petrone, L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07741-z · Cited by 34
Marchand, G. J., Masoud, A. T., Grover, S., King, A., Brazil, G., Ulibarri, H., Parise, J., Arroyo, A., Coriell, C., Goetz, S., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00698-8 · Cited by 42
Putman, M., Kennedy, K., Sirotich, E., et al. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00001-7 · Cited by 36
Complete Chemical Synthesis of Minimal Messenger RNA by Efficient Chemical Capping Reaction
Abe, N., Imaeda, A., Inagaki, M., Li, Z., Kawaguchi, D., Onda, K., Nakashima, Y., Uchida, S., Hashiya, F., Kimura, Y., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00996 · Cited by 37
Population immunity and vaccine protection against infection
Leshem, E., & Lopman, B. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00870-9 · Cited by 36
Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529
Wang, Q., Anang, S., Iketani, S., Guo, Y., Liu, L., Katsamba, P. S., Shapiro, L. S., Ho, D. D., & Sodroski, J. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110924 · Cited by 34
Burn, E., Li, X., Delmestri, A., Jones, N., Duarte‐Salles, T., Reyes, C., Martínez‐Hernández, E., Martí, E., Verhamme, K. M. C., Rijnbeek, P. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34668-w · Cited by 61
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V., Frankland, T. B., Xie, F., Ackerson, B. K., Valluri, S. R., Jodar, L., & McLaughlin, J. M. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00354-x · Cited by 36
Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases
Rouf, N. Z., Biswas, S., Tarannum, N., Oishee, L. M., & Muna, M. M. (2022) · RNA Biology · doi:10.1080/15476286.2022.2055923 · Cited by 41
“The similarities between SARS-CoV-2 and syncitin-1 spike proteins are only 8.8% and 15.8% for amino acid identity and amino acid sequence respectively.”
BackgroundMethodResultInfluentialLipid-based colloidal nanoparticles for applications in targeted vaccine delivery
Khan, M. S., Appak‐Baskoy, S., Yang, C. J., Hong, J., Chae, J., Ha, H.-J., Lee, S., Tanaka, M., Choi, Y., & Choi, J. H. (2023) · Nanoscale Advances · doi:10.1039/d2na00795a · Cited by 41
Delayed systemic urticarial reactions following mRNA COVID-19 vaccination
Pitlick, M. M., Joshi, A. Y., Gonzalez‐Estrada, A., & Chiarella, S. E. (2022) · Allergy and Asthma Proceedings · doi:10.2500/aap.2022.43.210101 · Cited by 35
“Contraindications to mRNA vaccination include a history of immediate allergic reaction to a component or previous dose of an mRNA COVID-19 vaccine.1,2 Althoughmuch attention has been given to immediate hypersensitivity to the vaccines, delayed reactions, including delayed cutaneous eruptions, do occur and have been re…”
BackgroundCarpenter, S. M., & Lu, L. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830482 · Cited by 41
Coronavirus disease 2019 vaccine hesitancy among children’s hospital staff: A single-center survey
Kociolek, L. K., Elhadary, J., Jhaveri, R. R., Patel, A. B., Stahulak, B. M., & CARTLAND, J. D. C. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.58 · Cited by 34
Thyroid Autoimmunity and SARS-CoV-2 Infection
Fallahi, P., Elia, G., Ragusa, F., Paparo, S. R., Patrizio, A., Balestri, E., Mazzi, V., Benvenga, S., Varricchi, G., Gragnani, L., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196365 · Cited by 46
“Later, new antiviral drugs and, above all, primary prophylaxis with vaccines [8], including first-time approved mRNA-based technology vaccines (Pfizer-Biontech’s BNT162b2 and Moderna’s mRNA-1273) [9,10], have changed radically over the course of COVID-19.”
Kong, Y. W., & Dreaden, E. C. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.879988 · Cited by 40
Marlin, R., Godot, V., Cardinaud, S., Galhaut, M., Coléon, S., Zurawski, S., Dereuddre‐Bosquet, N., Cavarelli, M., Gallouët, A.-S., Maisonnasse, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25382-0 · Cited by 44
Optic neuropathy after COVID-19 vaccination: a report of two cases
Elnahry, A. G., Asal, Z. B., Shaikh, N., Dennett, K. V., Elmohsen, M. N. A., Elnahry, G. A., Shehab, A. A., Vytopil, M., Ghaffari, L., Athappilly, G. K., et al. (2021) · International Journal of Neuroscience · doi:10.1080/00207454.2021.2015348 · Cited by 36
Ras-Carmona, A., Pelaez-Prestel, H. F., Lafuente, E. M., & Reche, P. A. (2021) · Cells · doi:10.3390/cells10102744 · Cited by 38
Mueller, T. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.03.007 · Cited by 39
Cutaneous reactions to COVID-19 vaccines: A review
Tan, S. W., Tam, Y. C., & Pang, S. M. (2022) · JAAD International · doi:10.1016/j.jdin.2022.01.011 · Cited by 38
“However, the median age and sex of the individuals were not documented.(3,4) 2.”
InfluentialAlternative splicing in lung influences COVID-19 severity and respiratory diseases
Nakanishi, T., Willett, J., Farjoun, Y., Allen, R. J., Guillén‐Guío, B., Adra, D., Zhou, S., & Richards, J. B. (2023) · Nature Communications · doi:10.1038/s41467-023-41912-4 · Cited by 35
Safford, H. C., Swingle, K. L., Geisler, H. C., Hamilton, A. G., Thatte, A. S., Ghalsasi, A. A., Billingsley, M. M., Alameh, M., Weissman, D., & Mitchell, M. J. (2023) · Small · doi:10.1002/smll.202303568 · Cited by 44
Kimura, M., Ferreira, V. H., Kothari, S. P., Pašić, I., Mattsson, J., Kulasingam, V., Humar, A., Mah, A., Delisle, J., Ierullo, M., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.07.024 · Cited by 38
“three-dose schedule of SARS-CoV-2 vaccination in the Allo-SCT setting appears to be similar to the general population.(3,4,34) T-cell immunity is less commonly analyzed in vaccine immunogenicity studies.”
BackgroundResultSakuraba, A., Luna, A., & Micić, D. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01233-3 · Cited by 36
“With the lack of effective treatments for COVID-19, prevention strategies including vaccination are of paramount importance in reducing the risk and mortality [8].”
BackgroundMatta, A., Kunadharaju, R., Osman, M., Jesme, C., McMiller, Z., Johnson, E. M., Matta, D., Kallamadi, R., & Bande, D. (2021) · Cureus · doi:10.7759/cureus.19240 · Cited by 41
“established the efficacy of mRNA vaccines reported any myocarditis [2,3].”
BackgroundNanoparticle and virus-like particle vaccine approaches against SARS-CoV-2
Kim, C., Kim, J.-D., & Seo, S. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-1608-z · Cited by 39
“Recent mRNA vaccines have shown high efficacy in protecting against SARS-CoV-2, with durable antibody and T cell responses (Polack et al., 2020; Baden et al., 2021; Hogan and Pardi, 2021).”
BackgroundEffectiveness of COVID-19 Vaccines in Adults with Diabetes Mellitus: A Systematic Review
van den Berg, J. M., Remmelzwaal, S., Blom, M. T., van Hoek, B. A. C. E., Swart, K. M. A., Overbeek, J. A., Burchell, G. L., Herings, R. M. C., & Elders, P. J. M. (2022) · Vaccines · doi:10.3390/vaccines11010024 · Cited by 41
Volk, A., Covini-Souris, C., Kühnel, D., de Mey, C., Römisch, J., & Schmidt, T. (2021) · BioDrugs · doi:10.1007/s40259-021-00511-9 · Cited by 37
Barnabas, R. V., & Wald, A. (2021) · Annals of Internal Medicine · doi:10.7326/m20-8060 · Cited by 36
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.